Intertek Acquires Melbourn Scientific
News Jul 10, 2013
It has expertise in all aspects of characterisation of orally inhaled and intra-nasal products (OINDP) and transdermal devices in addition to services for conventionally delivered medicines. There is an increasing demand worldwide for more patient friendly drug delivery methods for optimum therapeutic efficacy and efficiency and enhanced patient outcomes.
Its formulation services respond to the need for re-formulation of existing products to improve efficacy or extend patent life and to widen the market potential for a given product. Moving from injection to oral inhalation, for example, is a key strategy of many global Pharmaceutical majors to achieve increased market share by improving bioavailability and drug use uptake within a patient population (by improving delivery at the true target) whilst reducing patient trauma.
Located in Royston, near Cambridge, in the UK, Melbourn’s business employs 80 staff. It’s 20,000 sqft facility is Good Manufacturing Practice (GMP) compliant, regularly inspected by the UK Medicines and Health Regulatory Authority (MHRA) and the FDA. The company’s reputation for providing outstanding and responsive customer service along with its specialist skills have fostered loyal customer relationships of which Melbourn is especially proud and which complements Intertek’s existing technical capabilities and culture.
Dr. Andrew Swift SVP Intertek Chemicals and Pharmaceuticals, says "Combining Intertek’s GMP/ GLP pharmaceutical/ biopharmaceutical studies and our advanced capabilities for measuring device/ drug interaction with Melbourn’s expertise in OINDP drug characterisation provides a unique and compelling offering to clients. Adding in our global reach and Regulatory Services, Intertek now offers a comprehensive and global end to end expert service to support drug development which is unmatched by current competitors.”
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?READ MORE
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent painful swellings of the skin and mucous membranes. A new drug has been developed to help prevent attacks of hereditary angioedema. It has now been investigated in an international study performed at over 26 university facilities in Europe, Canada and Australia.READ MORE